Merck & Co’s., Inc. (NYSE: MRK) has declared that its Keytruda has received the approval of the FDA. FDA has given the green signal for the treatment of triple-negative breast cancer (TNBC) with Keytruda in combination with chemotherapy. FDA has supported Keytruda after